Cliff Asness's RCUS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 86,207 shares of Arcus Biosciences, Inc. (RCUS) worth $2.05 M, representing 0.00% of the portfolio. First purchased in 2019-Q4, this long-term strategic position has been held for 23 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in RCUS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 100,293 shares. Largest reduction occurred in Q2 2023, reducing 221,257 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Arcus Biosciences (RCUS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arcus Biosciences (RCUS) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +2,430 | Add 2.90% | 86,207 | $23.83 |
| Q3 2025 | -24,522 | Reduce 22.64% | 83,777 | $13.60 |
| Q2 2025 | +17,345 | Add 19.07% | 108,299 | $8.14 |
| Q1 2025 | +65,254 | Add 253.91% | 90,954 | $7.85 |
| Q4 2024 | -390 | Reduce 1.49% | 25,700 | $14.89 |
| Q3 2024 | +1,566 | Add 6.39% | 26,090 | $15.29 |
| Q2 2024 | +9,916 | Add 67.88% | 24,524 | $15.23 |
| Q1 2024 | +3,661 | Add 33.44% | 14,608 | $18.88 |
| Q4 2023 | +10,947 | New Buy | 10,947 | $19.10 |
| Q2 2023 | -221,257 | Sold Out | 0 | $0.00 |
| Q1 2023 | +100,293 | Add 82.91% | 221,257 | $18.24 |
| Q4 2022 | +856 | Add 0.71% | 120,964 | $20.68 |
| Q3 2022 | +49,775 | Add 70.77% | 120,108 | $26.16 |
| Q2 2022 | +70,333 | New Buy | 70,333 | $25.34 |
| Q4 2021 | -5,869 | Sold Out | 0 | $0.00 |
| Q3 2021 | -31,770 | Reduce 84.41% | 5,869 | $34.93 |
| Q2 2021 | -9,587 | Reduce 20.30% | 37,639 | $27.47 |
| Q1 2021 | -18,740 | Reduce 28.41% | 47,226 | $28.08 |
| Q4 2020 | +526 | Add 0.80% | 65,966 | $25.95 |
| Q3 2020 | +7,278 | Add 12.51% | 65,440 | $17.15 |
| Q2 2020 | +32,186 | Add 123.91% | 58,162 | $24.74 |
| Q1 2020 | -971 | Reduce 3.60% | 25,976 | $13.90 |
| Q4 2019 | +26,947 | New Buy | 26,947 | $10.09 |
Cliff Asness's Arcus Biosciences Investment FAQs
Cliff Asness first purchased Arcus Biosciences, Inc. (RCUS) in Q4 2019, acquiring 26,947 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Arcus Biosciences, Inc. (RCUS) for 23 quarters since Q4 2019.
Cliff Asness's largest addition to Arcus Biosciences, Inc. (RCUS) was in Q1 2023, adding 221,257 shares worth $4.04 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 86,207 shares of Arcus Biosciences, Inc. (RCUS), valued at approximately $2.05 M.
As of the Q4 2025 filing, Arcus Biosciences, Inc. (RCUS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Arcus Biosciences, Inc. (RCUS) was 221,257 shares, as reported at the end of Q1 2023.